This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Health Canada OK’s NKO Health Claims
September 29, 2010 - News
Comments

LAVAL, Quebec—Neptune Technologies & Bioressources Inc. announced the Canadian Minister of Health approved several therapeutic and risk reduction claims for NKO®, the company’s krill oil ingredient. According to the company, Health Canada spent two years reviewing substantial preclinical and clinical evidence relating to the safety and efficacy of NKO in relation to certain chronic diseases.

The following health claims were approved exclusively for NKO:

1. Cardiovascular health:

  • Helps to reduce the levels of LDL cholesterol (in conjunction with conventional statin therapy): 2 softgels (1 g) per day.
  • Helps to increase the levels of HDL cholesterol (in conjunction with conventional statin therapy): 2 softgels (1 g) per day.
  • Helps to reduce the levels of triglycerides (in conjunction with conventional statin therapy): 4 softgels (2 g) per day.

2. Inflammation:

  • Helps to reduce C-reactive protein levels, a clinical marker of inflammation: 1 softgel (0.5 g) per day.
  • Helps to reduce pain associated with osteoarthritis: 1 softgel (0.5 g) per day.

3. Women’s Health:

  • Helps to relieve symptoms of premenstrual syndrome (PMS): 4 softgels (2 g) per day.
  • Helps to relieve symptoms of dysmenorrhea: 4 softgels (2 g) per day.

André Godin, CFO, Neptune Technologies, commented: “Health claims are becoming among the most important drivers influencing the purchasing of omega-3 supplements worldwide. With this outstanding achievement, Neptune reinforces its leader position as a golden standard in the krill oil market."

In 2009, Health Canada approved certain health claims for omega-3s, although the new NKO claims are even stronger, according to Wael Massrieh, Ph.D., director of R&D for Neptune Technologies. He noted the strongest claim related to the ability of omega-3 products to reduce serum triglycerides at levels of 3 g to 10 g of fish oil per day, compared to the similar claim for NKO at only 2 g/d.

“The NKO approved claims are competitive when compared to the already approved claims for fish oils since not only have they been accepted at significantly much lower doses, but they also offer more specific health benefits in cardiovascular, joint and women health" Godin added. “This strategic milestone is expected to have a positive effect on sales because it fulfills new consumer requirements."

Sources:

Comments
comments powered by Disqus
Related News
News
ONTARIO, Canada—A  new study conducted by Nutrasource Diagnostic Inc. found concentrated
News
Krill oil lowers serum triglycerides without increasing low-density lipoprotein (LDL) cholesterol
News
Aker BioMarine is launching a pilot program, "How to Speak Krill", that will give
News
Aker BioMarine published a third study in the Journal of Functional Foods on its new Superba™ Krill
News
Research indicates Superba™ Krill powder supplementation may positively impact blood lipids in